ROCHESTER, N.Y., July 26, 2016 /PRNewswire/ -- Patient identification Platform (Patient iP), provider of site selection and
The Patient iP solution, recently recognized
"We are always interested in new offerings we can provide to our customers to help them deliver high quality medicine and also experience meaningful operational and financial improvements and these are the exact reasons we have partnered with Patient iP. With this engagement, MEDENT has the opportunity to directly enable new treatment options for patients and advance clinical research all the while driving service revenue many customers have been missing out on," said Gary Cuthbert, president of MEDENT.
Research studies have historically struggled to meet enrollment numbers and timelines due to lack of patient knowledge about medical research both generically, and often times specifically in relation to a chronic condition. The partnership between MEDENT and Patient iP is a win for patients whose providers utilize MEDENT as their EMR system since Patient iP will leverage blinded, aggregated patient data from MEDENT diagnosis, procedure, demographic and so forth against clinical trial criteria in a real-time, automated fashion. If and when records are flagged as potential matches to enrolling studies, the appropriate physicians' office will be alerted to take the next step with the patient around research participation.
"Beyond the value in supporting patient matching for clinical trial recruitment, I see tremendous utility for Patient iP as an enhancement to our MEDENT system. As an example, from the perspective of physicians contracting with payers, having Patient iP's granular view into individual patient health status matrixed with co-morbid and other conditions will help groups understand and position themselves more effectively as the transition to value-based medicine continues to unfold," added Stephen M. Rauh, MD, president and managing partner of Rochester Colon and Rectal Surgeons, P.C., a MEDENT customer since 1990. "In my 30-plus years practicing, this was unthinkable access to one's own clinical data for utilization in the ongoing quest to improve outcomes."
"There are billions of patient visits annually in the US yet effective trial recruitment is still a pressing concern for research sponsors. The value of patient data within an EMR system is immeasurable and our goal at Patient iP is to make it easy for groups to truly leverage the data they have amassed over the years with an eye towards patient engagement," said Michael Margiotta, founder and CEO, Patient identification Platform. "We are very excited for our partnership with MEDENT and the impact we can deliver to their customers and with no additional administrative burden to their end-user base."
About Patient identification Platform (Patient iP)
The patented Patient iP solution bridges many of the most significant and costly gaps encountered when sponsors and contract research organizations conduct clinical trials: timely patient identification and enrollment. Adoption of the Platform enables CROs to streamline operations, helps study sites leverage existing electronic patient health data, and provides life sciences organizations with the speed necessary to achieve first-mover status. Since Patient iP's unique technology allows for faster development and approval of drugs and therapies, patients too are benefactors of the solution's range of benefits given the potential for healthier and longer lives. For more information, visit us at www.patientip.com or follow us on Twitter @PatientIP.
MEDENT is a software development and services company focused on automating medical practices. We offer an All-In-One EMR/EHR, Patient Portal & Practice Management system providing a high-level of interoperability and automation. A recent Medical Economics survey ranked MEDENT EHR the #1 EHR system in the nation for the second year in a row. The MEDENT system is available in the cloud as a service or as a server based system in the medical practice. For more information, visit www.medent.com.
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/patient-identification-platform-and-medent-align-to-empower-clinical-trial-participation-300302587.html
SOURCE Patient identification Platform
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All